Davide M, Kamposioras K, Lampriani T, Mario D, Berardino B, Nadia H, Carl S, Joanna N, Dimitrios T, Flippo A, Hassan H, Antonios V, Konstantinos P, Stefanie C, Lazar P, Jindrich K, Andres R, Katarina A, Junlin Y, Lovey J, Primoz S, Haytham S, Ranveig R, Marzanna C, Olalla SC, Natalia C, Ramon A M, Giovanna AA, Farsid A, Radu V, Erjeta R, D T, Chirstos C, Irina I, Igor D, Branka P, Francesco C, Iglika M, Natalija DP, Cvetka GK, Elena T, Pantelis K, Panagiotis N, Ioanna G, Stefania G, Salih Y, Er Ö, Yasmina C, Kumaran G, Orges S, Aasim Y, Gono P, Apostolidis K, Tolia M
Rev Recent Clin Trials - (-) - [2021-10-28; online 2021-10-28]
Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.</P>.